Immunophenotypic studies of monoclonal gammopathy of undetermined significance

BMC Clinical Pathology

Volumn 8, Issue 1, 2008, Pages

  Olteanu, Horatiu ^a   Wang, Huan You ^b   Chen, Weina ^b   McKenna, Robert W ^b   Karandikar, Nitin J ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; LYMPHOCYTE MEMBRANE IMMUNOGLOBULIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PHENOTYPIC VARIATION; PLASMA CELL;

EID: 58149085556     PISSN: 14726890     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-8-13     Document Type: Article

References (33)

1. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. RA Kyle TM Therneau SV Rajkumar JR Offord DR Larson MF Plevak LJ Melton 3rd, N Engl J Med 2002 346 8 564 569 10.1056/NEJMoa01133202 11856795
2. Prevalence of monoclonal gammopathy of undetermined significance. RA Kyle TM Therneau SV Rajkumar DR Larson MF Plevak JR Offord A Dispenzieri JA Katzmann LJ Melton 3rd, N Engl J Med 2006 354 13 1362 1369 10.1056/NEJMoa054494 16571879
3. Monoclonal gammopathy of undetermined significance. RA Kyle SV Rajkumar, Br J Haematol 2006 134 6 573 589 10.1111/j.1365-2141.2006.06235.x 16938117
4. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. SV Rajkumar MQ Lacy RA Kyle, Blood Rev 2007 21 5 255 265 10.1016/j.blre.2007.01.002 17367905
5. Plasma cell neoplasms. TM Grogan B van Camp RA Kyle HK Mueller-Hermelink NL Harris, Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues Lyon: IARC, Jaffe ES, Harris NL, Stein H, Vardiman JW, 2001 142 156
6. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. FE Davies AM Dring C Li AC Rawstron MA Shammas SM O'Connor JA Fenton T Hideshima D Chauhan IT Tai, Blood 2003 102 13 4504 4511 10.1182/blood-2003-01-0016 12947006
7. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. M Perez-Andres J Almeida M Martin-Ayuso MJ Moro G Martin-Nunez J Galende D Borrego MJ Rodriguez F Ortega J Hernandez, Leukemia 2005 19 3 449 455 10.1038/sj.leu.2403647 15674420
8. An increase in MPC-1- and MPC-1-CD45+ immature myeloma cells in the progressive states of bone marrow plasmacytosis: the revised phenotypic classification of monoclonal marrow plasmacytosis (MOMP-2005). K Otsuyama H Asaoku MM Kawano, Int J Hematol 2006 83 1 39 43 10.1532/IJH97.05112 16443550
9. CD200 is a new prognostic factor in multiple myeloma. J Moreaux D Hose T Reme E Jourdan M Hundemer E Legouffe P Moine P Bourin M Moos J Corre, Blood 2006 108 13 4194 4197 10.1182/blood-2006-06-029355 16946299
10. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. M Ocqueteau A Orfao J Almeida J Blade M Gonzalez R Garcia-Sanz C Lopez-Berges MJ Moro J Hernandez L Escribano, Am J Pathol 1998 152 6 1655 1665 9626070
11. Four-color flow cytometric analysis of myeloma plasma cells. S Kobayashi R Hyo Y Amitani M Tanaka C Hashimoto R Sakai T Tamura S Motomura A Maruta, Am J Clin Pathol 2006 126 6 908 915 10.1309/VWXARAAG9DAPQ31Y 17153775
12. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. AC Rawstron FE Davies R DasGupta AJ Ashcroft R Patmore MT Drayson RG Owen AS Jack JA Child GJ Morgan, Blood 2002 100 9 3095 3100 10.1182/blood-2001-12-0297 12384404
13. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003 121 5 749 757 10.1046/j.1365-2141.2003.04355.x 12780789
14. Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. J Almeida A Orfao G Mateo M Ocqueteau R Garcia-Sanz MJ Moro J Hernandez F Ortega D Borrego A Barez, Pathol Biol (Paris) 1999 47 2 119 127 10192879
15. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells. O Sezer U Heider I Zavrski K Possinger, Haematologica 2001 86 8 837 843 11522540
16. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. AC Rawstron RG Owen FE Davies RJ Johnson RA Jones SJ Richards PA Evans JA Child GM Smith AS Jack, Br J Haematol 1997 97 1 46 55 10.1046/j.1365-2141.1997.72653.x 9136941
17. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. ME Sarasquete R Garcia-Sanz D Gonzalez J Martinez G Mateo P Martinez JM Ribera JM Hernandez JJ Lahuerta A Orfao, Haematologica 2005 90 10 1365 1372 16219573
18. Phenotypic difference of normal plasma cells from mature myeloma cells. H Harada MM Kawano N Huang Y Harada K Iwato O Tanabe H Tanaka A Sakai H Asaoku A Kuramoto, Blood 1993 81 10 2658 2663 8490175
19. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. P Lin R Owens G Tricot CS Wilson, Am J Clin Pathol 2004 121 4 482 488 10.1309/74R4TB90BUWH27JX 15080299
20. Immunophenotypic aberrations, DNA content, and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies. M Lima A Teixeira Mdos S Fonseca C Goncalves M Guerra ML Queiros AH Santos A Coutinho L Pinho L Marques, Blood Cells Mol Dis 2000 26 6 634 645 10.1006/bcmd.2000.0342 11358356
21. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. SA Ely DM Knowles, Am J Pathol 2002 160 4 1293 1299 11943714
22. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. AC Rawstron A Orfao M Beksac L Bezdickova RA Brooimans H Bumbea K Dalva G Fuhler J Gratama D Hose, Haematologica 2008 93 3 431 438 10.3324/haematol.11080 18268286
23. Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma. AC Seegmiller Y Xu RW McKenna NJ Karandikar, Am J Clin Pathol 2007 127 2 176 181 10.1309/5EL22BH45PHUPM8P 17210522
24. Primary pulmonary plasmacytoma involving bilateral lungs and marked hypergammaglobulinemia: differentiation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. N Niitsu M Kohri M Hayama H Nakamine N Nakamura M Bessho M Higashihara, Leuk Res 2005 29 11 1361 1364 10.1016/j.leukres.2005.04.009 15878199
25. The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis. D Joshua A Petersen R Brown B Pope L Snowdon J Gibson, Br J Haematol 1996 94 1 76 81 10.1046/j.1365-2141.1996.d01- 1784.x 8757512
26. A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy. R Bataille N Robillard C Pellat-Deceunynck M Amiot, Immunol Rev 2003 194 105 111 10.1034/j.1600-065X.2003.00039.x 12846811
27. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. E Perez-Persona MB Vidriales G Mateo R Garcia-Sanz MV Mateos AG de Coca J Galende G Martin-Nunez JM Alonso N de Las Heras, Blood 2007 110 7 2586 2592 10.1182/blood-2007-05-088443 17576818
28. High-Risk MGUS: Identification by Immunophenotype, Karyotype and Clonal Homogeneity. AC Rawstron JA Fenton D Gonzalez AM Dring SM O'Connor RG Owen SJ Richards AS Jack FE Davies JA Child, Blood 2003 102 11 36A
29. Multiple myeloma: increasing evidence for a multistep transformation process. M Hallek PL Bergsagel KC Anderson, Blood 1998 91 1 3 21 9414264
30. B cell maturation in relation to multiple myeloma. FK Stevenson SS Sahota, Pathol Biol (Paris) 1999 47 2 89 97 10192875
31. Multiple myeloma: evolving genetic events and host interactions. WM Kuehl PL Bergsagel, Nat Rev Cancer 2002 2 3 175 187 10.1038/nrc746 11990854
32. Isotype class switching and the pathogenesis of multiple myeloma. JA Fenton G Pratt AC Rawstron GJ Morgan, Hematol Oncol 2002 20 2 75 85 10.1002/hon.688 12111870
33. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. SV Rajkumar RA Kyle TM Therneau LJ Melton 3rd AR Bradwell RJ Clark DR Larson MF Plevak A Dispenzieri JA Katzmann, Blood 2005 106 3 812 817 15855274 10.1182/blood-2005- 03-1038